M22-418: A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine
Sponsor: AbbVie
Phase of Development: Phase III
Study Duration: Approximately 40 weeks
Enrollment Status: Open – Estimated end of screening in August 2024 Principal Investigator: Rajiv Aggarwal, M.D.
No current studies.